Conference Coverage

When to worry about congenital melanocytic nevi


 

EXPERT ANALYSIS FROM SDEF HAWAII DERMATOLOGY SEMINAR

Children born with two or more melanocytic nevi of any size should have an MRI to check for brain lesions, ideally within the first 6 months, according to Jennifer Huang, MD, a pediatric dermatologist at Boston Children’s Hospital.

Two or more nevi increase the risk of CNS involvement, which in turn increases the risk of malignant conversion by more than 16-fold.

Dr. Jennifer Huang

Dr. Huang’s advice came during a presentation at the Hawaii Dermatology Seminar provided by the Global Academy for Medical Education/Skin Disease Education Foundation.

Among the studies she cited was a 2017 literature review of 448 children with congenital nevi, 10 of whom developed melanoma: It arose in the skin in 2, the brain in 6, and an unknown location in 2. All 10 children were born with two or more nevi, and not all of them had large or giant nevi, which is a known risk factor for malignant conversion (Br J Dermatol. 2017 May;176[5]:1131-43).

Pages

Recommended Reading

Metastatic eccrine carcinoma with stomach and pericardial involvement
MDedge Hematology and Oncology
FDA expands approval of nivolumab for melanoma treatment
MDedge Hematology and Oncology
Desmoplastic melanoma yields to checkpoint inhibitors
MDedge Hematology and Oncology
Supportive oncodermatology: Cancer advances spawn new subspecialty
MDedge Hematology and Oncology
Neoadjuvant dabrafenib and trametinib improves event-free survival in resectable melanoma
MDedge Hematology and Oncology
Be alert for BAP1 mutations in hereditary melanomas
MDedge Hematology and Oncology
Melanoma incidence increased in older non-Hispanic whites
MDedge Hematology and Oncology
VIDEO: Gene test guides need for sentinel node biopsy in elderly melanoma patients
MDedge Hematology and Oncology
Concurrent ipilimumab and CMV colitis refractory to oral steroids
MDedge Hematology and Oncology
VIDEO: U.S. melanoma incidence hits all-time high
MDedge Hematology and Oncology